# 14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response

> **NCT00308048** · PHASE3 · COMPLETED · sponsor: **Ullevaal University Hospital** · enrollment: 435 (—)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** Pegylated Interferon alfa 2b and ribavirin

## Key facts

- **NCT ID:** NCT00308048
- **Lead sponsor:** Ullevaal University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2006-09
- **Target enrollment:** 435 (—)
- **Last updated:** 2011-07-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00308048

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00308048, "14 vs 24 Weeks HCV Treatment to Genotype 2/3 Patients With Rapid Virological Response". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT00308048. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*